Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
AIM: The goal of this study was to estimate the cumulative activity of (131)I to be administered to patients with distant metastases from thyroid carcinoma. METHODS: A total of 444 patients were treated from 1953-1994 for distant metastases from papillary and follicular thyroid carcinoma: 223 had lung metastases only, 115 had bone metastases only, 82 had both lung and bone metastases, and 24 had metastases at other sites. Treatment consisted of the administration of 3.7 GBq (100 mCi) (131)I after withdrawal of thyroid hormone treatment, every 3-9 months during the first 2 yr and then once a year until the disappearance of any metastatic uptake. Thyroxine treatment was given at suppressive doses between (131)I treatment courses. RESULTS: Negative imaging studies (negative total body (131)I scans and conventional radiographs) were attained in 43% of the 295 patients with (131)I uptake; more frequently in those who were younger, had well-differentiated tumors, and had a limited extent of disease. Most negative studies (96%) were obtained after the administration of 3.7-22 GBq (100-600 mCi). Almost half of negative studies were obtained more than 5 yr after the initiation of the treatment of metastases. Among patients who achieved a negative study, only 7% experienced a subsequent tumor recurrence. Overall survival at 10 yr after initiation of (131)I treatment was 92% in patients who achieved a negative study and 19% in those who did not. CONCLUSION: (131)I treatment is highly effective in younger patients with (131)I uptake and with small metastases. They should be treated until the disappearance of any uptake or until a cumulative activity of 22 GBq has been administered. In the other patients, other treatment modalities should be used when tumor progression has been documented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
Mazzaferri, E. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1447 · Cited by 1,396
Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Ackerman, L. V., & Rosaí, J. (1974) · Medical Entomology and Zoology · Cited by 1,043
Second primary malignancies in thyroid cancer patients
Rubino, C., de Vathaire, F., Dottorini, M. E., Hall, P., Schvartz, C., Couette, J. E., Dondon, M. G., Abbas, M. T., Langlois, C., & Schlumberger, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601319 · Cited by 655
Self-citationHistological Typing of Thyroid Tumours
Hedinger, C. (1988) · Springer eBooks · doi:10.1007/978-3-642-61383-8 · Cited by 630
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587
Schlumberger, M. J., Vathaire, C. C.-D., de Vathaire, F., Travagli, J. P., Gardet, P., Lumbroso, J., Francese, C., Fontaine, F., Ricard, M., & Parmentier, C. (1996) · PubMed · Cited by 498
Self-citationShimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Demers, L. M., & Spencer, C. A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01681.x · Cited by 460
Radioiodsne-131 In the Diagnosis and Treatment of Metastatic Weil Differentiated Thyroid Cancer
Maxon, H. R., & Smith, H. S. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30317-7 · Cited by 409
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationLenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Self-citationBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationCabanillas, M. E., McFadden, D. G., & Durante, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30172-6 · Cited by 1,430
Self-citationGuidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Self-citationTuttle, R. M., Tala, H., Shah, J., Leboeuf, R., Ghossein, R., Gonen, M., Brokhin, M., Omry, G., Fagin, J. A., & Shaha, A. (2010) · Thyroid · doi:10.1089/thy.2010.0178 · Cited by 924
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 727
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy
Jonklaas, J., Sarlis, N. J., Litofsky, D., Ain, K. B., Bigos, S. T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Ladenson, P. W., Magner, J., et al. (2006) · Thyroid · doi:10.1089/thy.2006.16.1229 · Cited by 695
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Self-citationThyroid Cancer Epidemiology and Prognostic Variables
Sipos, J. A., & Mazzaferri, E. L. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.05.004 · Cited by 514
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
“The remaining patients discontinued the drug because of disease progression (35 patients), adverse events (12), death ( 5 ), withdrawal of consent (1), an administrative decision (1), a protocol deviation (1), or the patient’s request (6).”
BackgroundSelf-citationTuttle, R. M., Ahuja, S., Avram, A. M., Bernet, V. J., Bourguet, P., Daniels, G. H., Dillehay, G., Draganescu, C., Flux, G., Führer, D., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0597 · Cited by 413
BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2707 · Cited by 397
Self-citationLupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1179 · Cited by 391
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Schlumberger, M., Brose, M., Elisei, R., Leboulleux, S., Luster, M., Pitoia, F., & Pacini, F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70215-8 · Cited by 377
Self-citationLeboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
Self-citationThyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq190 · Cited by 350
Current practice in patients with differentiated thyroid cancer
Schlumberger, M., & Leboulleux, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00448-z · Cited by 342
Self-citationCarling, T., & Udelsman, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-105739 · Cited by 328
The Na+/I− Symporter (NIS): Mechanism and Medical Impact
Portulano, C., Paroder-Belenitsky, M., & Carrasco, N. (2014) · Endocrine Reviews · doi:10.1210/er.2012-1036 · Cited by 319
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds230 · Cited by 290
Fugazzola, L., Elisei, R., Fuhrer, D., Jarzab, B., Leboulleux, S., Newbold, K., & Smit, J. (2019) · European Thyroid Journal · doi:10.1159/000502229 · Cited by 285
Self-citationBonnet, S., Hartl, D., Leboulleux, S., Baudin, E., Lumbroso, J. D., Al Ghuzlan, A., Chami, L., Schlumberger, M., & Travagli, J. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1931 · Cited by 275
Self-citationMauri, G., Hegedüs, L., Bandula, S., Cazzato, R. L., Czarniecka, A., Dudeck, O., Fugazzola, L., Netea-Maier, R., Russ, G., Wallin, G., et al. (2021) · European Thyroid Journal · doi:10.1159/000516469 · Cited by 270
Yoo, S.-K., Song, Y. S., Lee, E. K., Hwang, J., Kim, H. H., Jung, G., Kim, Y. A., Kim, S.-J., Cho, S. W., Won, J.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10680-5 · Cited by 268
Bone metastases from differentiated thyroid carcinoma
Muresan, M. M., Olivier, P., Leclere, J., Sirveaux, F., Brunaud, L., Klein, M., Zarnegar, R., & Weryha, G. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0229 · Cited by 260
Brose, M. S., Robinson, B., Sherman, S. I., Krajewska, J., Lin, C.-C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., Hernando, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00332-6 · Cited by 256
Oh, J. M., & Ahn, B.-C. (2021) · Theranostics · doi:10.7150/thno.57689 · Cited by 163
New therapeutic approaches for metastatic thyroid carcinoma
Baudin, E., & Schlumberger, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70034-7 · Cited by 143
Self-citationShonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Capdevila, J., & Stjepanovic, N. (2014) · Biologics: Targets and Therapy · doi:10.2147/btt.s39381 · Cited by 85
Byeon, H. K., Na, H. J., Yang, Y. J., Ko, S., Yoon, S. O., Ku, M., Yang, J., Kim, J. W., Ban, M. J., Kim, J.-H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13480 · Cited by 29
“Even the differentiated thyroid carcinomas which generally have an excellent prognosis, show disappointing treatment outcomes in patients with extensive local invasion or distant metastases [12,13].”
BackgroundMischler, K., Kneifel, S., & Cathomas, R. (2016) · Oncology Research and Treatment · doi:10.1159/000448387 · Cited by 4
Metadata
- Authors
- Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., & Schlumberger, M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-08-01
- Volume
- 91
- Issue
- 8
- Pages
- 2892-2899
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2040642592
- Cited by
- 1,675
- References
- 28
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.